Some aspects of application of the combination of formoterol and budesonide: what is changed?

Abstract

The use of a combination of the inhaled glucocorticosteroid budesonide and beta2-selective long-acting adrenergic agonist formoterol is recommended for both bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD), however, indications for their use have changed significantly over the past 20 years. In BA, there was a transition from regular dosing to the tactics of a single drug – regularly and on demand, to the last recommendation – to apply as necessary at all stages of BA treatment. In COPD, this combination was a universal drug for the treatment of severe COPD with frequent exacerbations or in combination with BA, and now not only the severity and frequency of exacerbations, but also the level of blood eosinophilia is taken into account. The combination of budesonide / formoterol, which is important for practical health care, has become more accessible in recent years thanks to the advent of a domestic reconstituted drug with an original capsule powder inhaler. The drug went through comparative studies with the original drug both in clinical efficacy and in the properties of the delivered particles.